Axsome Therapeutics' GAAP loss for 9M 2021 was $96.427 million, up 30.8% from $73.736 million in the prior year.
Axsome Therapeutics' GAAP loss for 9M 2021 was $96.427 million, up 30.8% from $73.736 million in the prior year.
Financial results
Axsome Therapeutics' GAAP loss for 9M 2021 was $96.427 million, up 30.8% from $73.736 million in the prior year. 
axsometherapeuticsinc.gcs-web.com News feed
English (US) 